Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 1/20 | 0.33 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | CASP1 | P29466 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11332380 | 0.97 | TSHR (0.36) | CHRM2CHRM1MEN1LMNAKMT2A | |
| SCHEMBL7540286 | 0.97 | TSHR (0.36) | CHRM2CHRM1MEN1LMNAKMT2A | |
| SCHEMBL13130680 | 0.78 | CHRM2 (0.31) | CHRM2CHRM1 | |
| SCHEMBL3275964 | 0.78 | CHRM2 (0.31) | CHRM2CHRM1 | |
| SCHEMBL11373180 | 0.75 | MEN1 (0.32) | MEN1LMNAKMT2ANPSR1TSHR | |
| SCHEMBL11373956 | 0.73 | MEN1 (0.31) | MEN1LMNAKMT2ANPSR1TSHR | |
| SCHEMBL10081295 | 0.72 | CHRM2 (0.34) | CHRM2CHRM1 | |
| SCHEMBL11381056 | 0.71 | MEN1 (0.30) | MEN1KMT2A | |
| SCHEMBL13130688 | 0.70 | CHRM2 (0.33) | CHRM2CHRM1 | |
| SCHEMBL214300 | 0.69 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8563732-B2 | Oxyimino compounds and the use thereof | SHIONOGI & CO., LTD. (JP) | 2013-10-22 | — | — | US | disclosed |
| US-20120059162-A1 | FUSED IMIDAZOLE DERIVATIVE HAVING TTK INHIBITORY ACTION | ONCOTHERAPY SCIENCE, INC. (JP) | 2012-03-08 | — | — | US | disclosed |
| US-20120059162-A1 | FUSED IMIDAZOLE DERIVATIVE HAVING TTK INHIBITORY ACTION | ONCOTHERAPY SCIENCE, INC. (JP) | 2012-03-08 | — | — | US | disclosed |
| US-20100240703-A1 | OXYIMINO COMPOUNDS AND THE USE THEREOF | PURDUE PHARMA L.P. | 2010-09-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120059162-A1 | FUSED IMIDAZOLE DERIVATIVE HAVING TTK INHIBITORY ACTION | NR0B1, GRK7, NR5A2 | CHRM2 480/4885CHRM1 530/4885MEN1 3210/4885 |
| US-20100240703-A1 | OXYIMINO COMPOUNDS AND THE USE THEREOF | CACNA1A, CACNA1S, OPRM1 | CHRM2 105/4885CHRM1 38/4885MEN1 2609/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.